Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-06-07
1999-03-09
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544326, 544327, 544328, 544329, C07D23948, A61K 31505
Patent
active
058801308
DESCRIPTION:
BRIEF SUMMARY
This application claims benefit of international application PCT/GB94/02659 filed Dec. 5, 1994.
The invention relates to pyrimidine derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-cell-proliferation activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrimidine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cell-proliferation effect in a warm-blooded animal such as man.
Many of the current treatment regimes for cancer utilise compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on the rapidly dividing tumour cells can be beneficial. Alternative approaches to anti-cancer agents which act by mechanisms other than the inhibition of DNA synthesis have the potential to display enhanced selectivity of action against cancer cells.
In recent years it has been discovered that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene i.e. a gene which, on activation, leads to the a formation of malignant tumour cells (Bradshaw, Mutagenesis, 1986, 1, 91). Several such oncogenes give rise to the production of peptides which are receptors for growth factors. The growth factor receptor complex subsequently leads to an increase in cell proliferation. It is known, for example, that several oncogenes encode tyrosine kinase enzymes and that certain growth factor receptors are also tyrosine kinase enzymes (Yarden et al., Ann. Rev. Biochem., 1988, 57, 443; Larsen et al. Ann. Reports in Med. Chem. 1989, Chpt. 13).
Receptor tyrosine kinases are important in the transmission of biochemical signals which initiate cell replication. They are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor (EGF) and an intracellular portion which functions as a kinase to phosphorylate tyrosine amino acids in proteins and hence to influence cell proliferation. Various classes of receptor tyrosine kinases are known (Wilks, Advances in Cancer Research, 1993, 60, 43-73) based on families of growth factors which bind to different receptor tyrosine kinases. The classification includes Class I receptor tyrosine kinases comprising the EGF family of receptor tyrosine kinases such as the EGF, NEU, erbB, Xmrk, DER and let23 receptors, Class II receptor tyrosine kinases comprising the insulin family of receptor tyrosine kinases such as the insulin, IGFI and insulin-related receptor (IRR) receptors and Class III receptor tyrosine kinases comprising the platelet-derived growth factor (PDGF) family of receptor tyrosine kinases such as the PDGFA, PDGFP and colony-stimulating factor 1 (CSF1) receptors. It is known that Class I kinases such as the EGF family of receptor tyrosine kinases are frequently present in common human cancers such as breast cancer (Sainsbury et al., Brit. J. Cancer, 1988, 58, 458; Guerin et al., Oncogene Res., 1988, 3, 21), squamous cell cancer of the lung (Hendler et al., Cancer Cells, 1989, 7, 347), bladder cancer (Neal et al., Lancet, 1985, 366), oesophageal cancer (Mukaida et al, Cancer, 1991, 68, 142), gastrointestinal cancer such as colon, rectal or stomach cancer (Bolen et al., Oncogene Res., 1987, 1, 149), leukaemia (Konaka et al., Cell, 1984, 37, 1035) and ovarian, bronchial or pancreatic cancer (European Patent Specification No. 0400586). As further human tumour tissues are tested for the EGF family of receptor tyrosine kinases it is expected that its widespread prevalance will be established in further cancers such as thyroid and uterine cancer. It is also known that EGF type tyrosine kinase activity is rarely detected in normal cells whereas it is more frequently detectable in malignant cells (Hunter, Cell, 1987, 50, 823). It has been shown more recently (W J Gullick, Brit. Med. Bull., 1991
REFERENCES:
patent: 5707995 (1998-01-01), Munro et al.
Wheeler et al, Chemical Abstracts vol. 113, entry 212003.
Fry et al.; A Specific Inhibitor of the Epiderman Growth Factor Receptor Tyrosine Kinase; Science; 19 Aug. 1994; pp. 1093-1095.
Buchdunger et al.; 4,5-Dianilinophthalimide: A protein-tyrosine kinase . . . transduction pathway and potent in vivo activity; Proc. Natl. Acad. Sci. USA, Mar. 1994; pp. 2334-2338.
Ward et al.; Epidermal Growth Factor Receptor Tyrosine Kinase; Biochemical Pharmacology; 1994; pp. 659-666.
Rewcastle et al.; Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships . . . Domain of the Epidermal Growth Factor Receptor; J. Med. Chem.; 1995, pp. 3482-3487.
Spence; Inhibitors of Tyrosine Kinase Activity as Anticancer Therapeutics: Recent Developments; Current Drugs Ltd., Anticancers etc., Patent Update; Therapeutic Patents, Jan. 1993; pp. 3-9.
Spada et al., Small molecule inhibitors of tyrosine kinase activity; Ex. Opin. Ther. Patents; 1995, pp. 805-817.
Bridges; The current status of tyrosine kinase inhibitors: . . . EGF receptor represent a new beginning?; Ex. Opin. Ther. Patents; 1995.
Traxler et al.; Recent advances in protein tyrosine kinase inhibitors; Drugs of the Future; 1995; pp. 1261-1274.
Abstract, WO 95/09847 (German), 13 Apr. 1995; Derwent Abstract 95/155198/20.
Abstract, WO 95/09851 (German), 13 Apr. 1995; Derwent Abstract 95/ 155200/20.
Abstract, WO 95/09852 (German), 13 Apr. 1995; Derwent Abstract 95/ 155201/20.
Abstract, WO 95/ 09853 (German), 13 Apr. 1995; Derwent Abstract 95/ 155202/20.
Burke: "Protein-tyrosine kinase inhibitors", Drugs Of The Future, vol. 17, No. 2, 1992, pp. 119-131, see the whole document.
Trinks, et al: "Dianilinophthalimides: Potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase", Journal Of Medicinal Chemistry, vol. 37, No. 7, Apr. 1, 1994, pp. 1015-1027, see the whole document.
Derwent Abstract No. 85-099057/ 17 of AU 84/32450 (equivalent to and EPA 139613 cited in Jun. 7, 1996 PTO-1449.
Derwent Abstract 87-343301/49 (EP-248349 cited in Jun. 7, 1996 PTO-1449).
Derwent Abstract 92-400924/49 (EP 516588 cited in Jun. 7, 1996 PTO-1449).
Derwent Abstract 93-313740/40 (EP 564409 cited in Jun. 7, 1996 PTO-1449).
Ford John M.
Zeneca Limited
LandOfFree
4,6-dianilino-pyrimidine derivatives, their preparation and thei does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4,6-dianilino-pyrimidine derivatives, their preparation and thei, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4,6-dianilino-pyrimidine derivatives, their preparation and thei will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321379